Streamlined proteomic / pharmaceutical assay platforms

Correlia Biosystems specializes in advanced protein quantification technologies, primarily through its PIXI platform, which offers a next-generation automated immunoassay system. This platform utilizes proprietary microfluidic gel technology to enhance the efficiency and accuracy of protein measurement, significantly reducing the turnaround time compared to traditional ELISA methods. The PIXI system is designed to require minimal sample volume—only 1 µL—while providing a broad dynamic range of detection, allowing for the analysis of both high and low concentration samples. This capability is particularly beneficial for applications in biopharmaceutical analysis, cell and gene therapy, and synthetic biology, enabling researchers to conserve precious biosamples and streamline their laboratory workflows.

The PIXI platform is characterized by its fully automated operation, which minimizes manual intervention and ensures reproducible results with a low coefficient of variation (CV) of 10%. It supports high-throughput analysis, capable of processing up to 96 samples simultaneously, and delivers results in as little as 30 minutes. The system is compatible with various liquid handling robots and fluorescent imaging systems, making it adaptable to existing laboratory setups. Additionally, Correlia offers both off-the-shelf and customizable assay solutions, allowing researchers to tailor the PIXI platform to their specific needs, thereby accelerating scientific discovery in the proteomics field.

United States

Correlia Biosystems develops innovative microscale tools that accelerate the rate of molecular interactions for rapid measurements of biomolecules. 

The customizable PIXI​ platform opens up new biological questions for interrogation from less than two microliters of sample, with rapid results that allow for dynamic monitoring of protein expression profiles.

Correlia Biosystems

Company Details